EN
SINOVAC's Anflu Influenza Vaccine Passes WHO Prequalification
On November 02, 2026, the World Health Organization (WHO) confirmed that Anflu, a trivalent split-virion influenza vaccine manufactured by SINOVAC, was prequalified. Anflu is the fourth SINOVAC vaccine prequalified by WHO, following the Hepatitis A Vaccine (Human Diploid Cell), Inactivated, the Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains, and the Varicella Vaccine, Live. The prequalified presentation is 0.5 mL single-dose vial, and is indicated for people aged 6 months and older.
Anflu's prequalification listing on the WHO website
Over the past 20 years, SINOVAC has continued to develop influenza vaccines, refine its manufacturing processes, and study the use of its vaccines in different populations. The company has supplied more than 150 million doses of its seasonal influenza vaccines, including both trivalent influenza vaccine and quadrivalent influenza vaccine, to nearly 20 countries and regions. Its seasonal influenza vaccines were the only mainland China–manufactured vaccines supplied to Hong Kong and Macao.
On the 20th anniversary of its launch in China, the WHO Prequalification makes Anflu eligible for procurement by United Nations (UN) agencies and positions it to support influenza prevention and control in more countries and regions. It also extends SINOVAC's portfolio of WHO-prequalified vaccines to include a seasonal influenza vaccine.
UN agencies rely on WHO prequalification to assess vaccines for procurement. WHO evaluates the vaccine's quality, safety, and efficacy, as well as the manufacturer's quality management system. Prequalification can also help countries assess vaccines for their own public procurement programs, supporting wider international access.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Four of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), the live attenuated varicella vaccine, and the trivalent split-virion influenza vaccine Anflu.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.